Abyrx

What Abyrx does

Abyrx, Inc. is a privately-held specialty biosurgical device company founded in 2013 and headquartered in Stamford, Connecticut. The company develops, manufactures, and distributes synthetic hemostatic bone putties and resorbable biomaterials used during orthopedic, trauma, spine, sports medicine, cranial, maxillofacial, and cardiothoracic surgical procedures. Its core technology platform is built on proprietary polymer chemistry licensed from Bezwada Biomedical, combined with in-house calcium phosphate and Vitamin E Acetate formulations, protected by over 50 issued and pending patents globally.

The product portfolio comprises five synthetic, tissue-free hemostatic bone putties differentiated by absorption profile and handling characteristics: AHBP (8-day absorption), HEMASORB (30-day resorption) plus its syringe applicator variant HEMASORB apply, HEMASORB PLUS (cleared for 1:1 mixing with autograft), and MONTAGE, marketed as the only cohesive, settable, and resorbable bone putty. MONTAGE received FDA clearance for cardiothoracic sternotomy in September 2023, extending the company's cleared indications to include bone hemostasis, bony void filling, and cranial bone cement use. Abyrx sells through a network of medical product distributors into hospitals and surgery centers, has recorded over 250,000 uses in the United States, and operates with a headcount of 11-50 employees.

In November 2025, Abyrx completed a $450 million transaction with Kairuku to form MedEdge Holdings LLC, a management-led buyout structured to fund acquisitions of commercial-stage surgical product companies. The combined entity now operates Abyrx's product portfolio alongside Kairuku's distributor-engagement SaaS platform, signaling a strategic shift from a single-product company toward a roll-up platform for surgical specialty assets.

Name

Abyrx

Legal name

ABYRX, Inc.

Website

http://www.abyrx.com/

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Abyrx is a privately-held specialty biosurgical device company that develops and distributes synthetic, resorbable hemostatic bone putty products to hospitals and surgery centers for orthopedic, trauma, spine, cranial, maxillofacial, and cardiothoracic surgical procedures.

Ownership category

akta.pro rank

Product category

Surgical Biomaterials / Specialty Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industry

Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL)

Keywords

• Hemostatic bone putty
• Resorbable biomaterials
• Surgical hemostasis devices
• Synthetic bone void filler
• Orthopedic surgical putty

Headquarters

HQ city

Irvington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Surgical Biomaterial Products: Abyrx generates revenue through the sale of its proprietary surgical therapeutic devices, including hemostatic bone putty products (HEMASORB, HEMASORB PLUS, MONTAGE, AHBP). These are one-time use medical devices sold to hospitals and surgery centers for use during surgical procedures. Products are available in various delivery formats including syringe-like applicators and surgical mesh.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Abyrx develops, manufactures, and sells a portfolio of FDA-cleared, synthetic, resorbable hemostatic bone putty products—AHBP, HEMASORB, HEMASORB apply, HEMASORB PLUS, and MONTAGE—for use by surgeons to control bone bleeding and fill bony voids during orthopedic, trauma, spine, cranial, maxillofacial, and cardiothoracic procedures. The single-use putties are sold in various delivery formats (syringe-like applicator, surgical mesh) and are engineered to resorb during natural bone remodeling.

Product overview

Abyrx developed a first-in-class materials science platform with an initial focus on therapeutic devices for surgical procedures. Their portfolio includes five synthetic hemostatic bone putty products: AHBP (absorbs within 8 days for rapid absorption needs), HEMASORB (resorbs within 30 days for moderate-to-heavy bleeding), HEMASORB apply (syringe-like applicator for difficult-to-access surfaces), HEMASORB PLUS (contains HA/β-TCP, cleared for autograft mixing), and MONTAGE (the only settable, resorbable bone putty that hardens within minutes). Products are used during orthopedic, trauma, spine, sports medicine, cranial, maxillofacial, and cardiothoracic procedures, consolidating features surgeons want into easy-to-use formats.

Differentiator

Problem solved

Functional benefit

Brands

• MONTAGE: Settable, resorbable bone putty that adheres to bleeding bone surfaces. The only cohesive, settable, and resorbable bone putty that is putty-like immediately upon opening. Available in MONTAGE Fast Set, MONTAGE Flowable, and PERMATAGE versions.
• HEMASORB
• HEMASORB PLUS
• AHBP

Products and services

• AHBP (Absorbable Hemostatic Bone Putty) Synthetic, tissue-free hemostatic bone putty for use on light-to-moderate bleeding bone; substantially absorbs within 8 days post-implantation and is associated with new bone formation observed at 14 days. Sold to hospitals and surgery centers for use during orthopedic, trauma, spine, cranial, maxillofacial, and cardiothoracic procedures.
• HEMASORB Resorbable Hemostatic Bone Putty Synthetic, tissue-free resorbable hemostatic bone putty that substantially resorbs within 30 days, designed to control bone bleeding reliably during surgical procedures. Sold to hospitals and surgery centers.
• HEMASORB apply Syringe-Like Applicator HEMASORB hemostatic bone putty delivered via syringe-like applicator for ease of application to bleeding bone surfaces that are difficult to access. Synthetic and substantially resorbs within 30 days.
• HEMASORB PLUS Resorbable Hemostatic Bone Putty Non-settable resorbable hemostatic bone putty containing calcium phosphate and Vitamin E Acetate, cleared for use in a 1:1 ratio with autograft—reducing the autograft harvest volume needed by half. Putty-like, ready-to-use without kneading or warming, and controls bleeding via mechanical tamponade.
• MONTAGE Settable, Resorbable Bone Putty The only cohesive, settable, and resorbable hemostatic bone putty that adheres to bleeding bone surfaces and is putty-like immediately upon opening. Two putties hand-mix in 45 seconds, harden within minutes, and fully resorb during bone remodeling. Primarily calcium phosphate with Vitamin E Acetate; cleared for bone hemostasis, filling bony voids in the skeletal system, and as a cranial bone cement, with clearances also for cardiothoracic surgery following sternotomy.

Quantifiable outcome

• ~30% greater new bone formation in critical sized defect animal model at 12-week time point compared to leading settable calcium phosphate bone void filler
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• KairukuflagshipStrategic or Co-development Partner · 1 November 2025Abyrx and Kairuku completed a $450 million transaction to form MedEdge Holdings LLC. This management-led buyout with new capital enables acquisition strategy. The new holding company leverages Abyrx's surgical products platform combined with Kairuku's SaaS platform for medical product distributors. The combined entity aims to facilitate acquisitions and boost commercialization of surgical products.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Smith & Nephew: Smith & Nephew has a regenerative medicine portfolio including bone graft substitutes and surgical hemostasis products. It competes with Abyrx across multiple surgical specialties where bone void filling and hemostasis are required.
• Medtronic: Medtronic is a large incumbent with bone graft substitute and spinal biologics offerings (including Infuse Bone Graft). It competes with Abyrx in spine and orthopedic surgical procedures where bone void filling and hemostasis products are used.
• Ethicon (Johnson & Johnson): Ethicon, a J&J subsidiary, dominates the surgical hemostasis and suture markets and is also the historical employer of Abyrx's scientific founders (Monocryl, Vicryl inventors). Ethicon's broad surgical portfolio competes in the operating room and overlaps with Abyrx's bone hemostasis applications.
• Zimmer Biomet: Zimmer Biomet is a major orthopedic device manufacturer with bone graft substitute and regenerative product lines. It competes with Abyrx in orthopedic and trauma surgical settings requiring bone void fillers and bone hemostasis.
• Stryker: Stryker is a leading orthopedic medical device company with significant orthobiologics and bone graft substitute offerings. It competes broadly with Abyrx in trauma, spine, and orthopedic surgical procedures where bone void filling and hemostasis are required.
• Baxter International: Baxter manufactures Floseal and other surgical hemostasis products used during surgical procedures, directly overlapping with Abyrx's hemostatic bone putty portfolio. It is a broad incumbent in biosurgical and hemostatic agents across multiple surgical specialties.

Regional players

• Artivion: Artivion (formerly CryoLife) manufactures biosurgical and hemostatic products for surgical procedures, including cardiac surgery. Its surgical hemostasis portfolio overlaps with Abyrx's MONTAGE cardiothoracic indication, particularly following sternotomy procedures.

Direct peers

• SeaSpine Holdings: SeaSpine is a focused orthobiologics and spinal implant company offering bone graft substitutes and synthetic biologics for spine surgery. It is a direct peer to Abyrx in the synthetic bone graft and bone void filler category.
• Orthofix Medical: Orthofix offers orthobiologics including bone graft substitutes used in spine and orthopedic surgery. Its bone void filler and biologics portfolio directly overlaps with Abyrx's HEMASORB and MONTAGE products.
• Integra LifeSciences: Integra LifeSciences offers DuraGen, bone graft substitutes, and regenerative tissue technologies for surgical use. Its portfolio of resorbable and synthetic implantable biomaterials closely mirrors Abyrx's hemostatic and resorbable bone putty products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/abyrx
• Facebookfacebook.com/abyrx
• LinkedInlinkedin.com/company/abyrx

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abyrx